Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: PGxRecEx02 - JSON Representation

Raw json | Download

{
  "resourceType" : "Task",
  "id" : "PGxRecEx02",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Task PGxRecEx02</b></p><a name=\"PGxRecEx02\"> </a><a name=\"hcPGxRecEx02\"> </a><a name=\"PGxRecEx02-en-US\"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org LA26421-0}\">Consider alternative medication</span></p><p><b>description</b>: voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Adam B. Everyman  Male, DoB: 1951-01-20 ( Medical Record Number: m123\u00a0(use:\u00a0usual,\u00a0))</a></p><p><b>reasonReference</b>: <a href=\"Observation-TxImp02.html\">Poor metabolizer</a></p></div>"
  },
  "status" : "requested",
  "intent" : "proposal",
  "code" : {
    "coding" : [
      {
        "system" : "http://loinc.org",
        "code" : "LA26421-0",
        "display" : "Consider alternative medication"
      }
    ]
  },
  "description" : "voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.",
  "for" : {
    🔗 "reference" : "Patient/CGPatientExample01"
  },
  "reasonReference" : {
    🔗 "reference" : "Observation/TxImp02",
    "display" : "Poor metabolizer"
  }
}